Challenged claims of The Johns Hopkins University’s patent directed to anti-cancer therapies that block immune system checkpoints, including the programmed death-1 receptor, are unpatentable as anticipated by and obvious over prior art, the Patent Trial and Appeal Board said, in an inter partes review by Merck Sharp & Dohme LLC. The board determined that the claims are anticipated by and obvious over various combination of prior art, including a report titled “Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable Tumors,” a study that looks at whether MK-3475 is effective and safe in three different patient populations, and a ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.